AbbVie Inc.

New York Stock Exchange
Back to all articles
Bullish +75

3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st - 24/7 Wall St.

AI-generated analysis

📈 AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering growth prospects at a valuation below the S&P 500 average.

💰 The company raised its quarterly dividend by 5.5% to $1.73 per share and lifted full-year adjusted EPS guidance to $14.08-$14.28.

🚀 Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.

📊 Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion.

🛡️ AbbVie has already crossed the biosimilar patent cliff that Merck faces in 2028, positioning it ahead of key competitors.

📉 The stock exhibits low volatility with a beta of 0.28 compared to the broader market's higher risk profile.

🎯 Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings from analysts.

💼 Immunology revenue grew 16.4% in Q1 as the two new drugs replaced Humira as the primary growth drivers.

Bullish Signals
  • AbbVie trades at a forward P/E of 18x with a PEG ratio of 0.43, offering attractive valuation relative to growth prospects and below the S&P 500 average.
  • The company increased its quarterly dividend by 5.5% to $1.73 per share and raised full-year adjusted EPS guidance to $14.08-$14.28, signaling strong income coverage.
  • Skyrizi and Rinvoq combined generated $6.6 billion in Q1 2026 revenue, with Skyrizi growing 30.9% YoY and Rinvoq growing 23.3% YoY.
  • Management raised full-year sales guidance for Skyrizi to $21.6 billion and for Rinvoq to $10.2 billion, projecting nearly $32 billion in annual sales.
  • The stock has a beta of 0.28, providing low volatility compared to the broader market while maintaining significant growth momentum.
  • Wall Street consensus price target is $267.79 across 16 Buy and 8 Strong Buy ratings, indicating strong analyst confidence in the current valuation.
Full Analysis
AbbVie (NYSE: ABBV) is positioned ahead of its July 31 Q2 earnings report with strong momentum driven by two blockbuster immunology drugs, Skyrizi and Rinvoq. These products combined generated $6.6 billion in revenue during the first quarter of 2026, effectively replacing Humira as the company's primary growth engines. Management has raised full-year guidance for both drugs to $21.6 billion and $10.2 billion respectively, signaling confidence that they will generate nearly $32 billion in annual sales. The stock currently trades at a forward P/E of 18x with a PEG ratio of 0.43, presenting a valuation below the S&P 500 average while offering low volatility with a beta of 0.28. Wall Street consensus targets the stock at $267.79, slightly above the current price of $265.52, supported by 16 Buy and 8 Strong Buy ratings. The company recently increased its quarterly dividend by 5.5% to $1.73 per share, lifting full-year adjusted EPS guidance to a range of $14.08 to $14.28. AbbVie has successfully navigated the patent cliff that rivals Merck and Pfizer are currently facing or will face in the coming years. While Humira revenue continues to decline due to biosimilar competition, the company's overall trajectory is defined by the rapid expansion of its newer portfolio. The upcoming earnings report on July 31 is expected to confirm whether these new products can sustain growth and support further increases to full-year guidance.